Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T16:49:58.334Z Has data issue: false hasContentIssue false

Chapter 2 - Novel therapeutic targets for treating affective disorders

Published online by Cambridge University Press:  19 October 2021

By
Eliyahu Dremencov  and
Thomas I. F. H. Cremers
Edited by
Chad E. Beyer  and
Stephen M. Stahl
Chad E. Beyer
Affiliation:
University of Colorado School of Medicine
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Prevalence of depression has increased progressively over the last decades. Besides the impact on human quality of life, the pharmaco-economical impact of this syndrome requires ongoing development of newer, more powerful antidepressants. While optimizing existing therapeutic compounds, multiple approaches can be taken to generate superiority over these compounds. The delay in onset of action of antidepressants is of relevance as the presence of side effects during the initial absence of clinical effects causes low therapy compliance. Obviously, a decrease in onset of action would overcome this problem. Current therapy still induces considerable side effects depending on the class of antidepressants used. Reducing these has multiple advantages, such as it will increase compliance but also facilitate the rapid and safe initiation of drug treatment. In line with safety requirements is the notion that new antidepressants should not be prone to hazardous effects in overdose, nor should they induce dangerous interactions by interfering with other treatment. Finally, it is currently recognized that depression is a cluster of symptoms rather than a concise disease. To this end, it is recognized that more tailored treatments might be required in the future. Arguably targeting subsymptoms and comorbid features such as anxiety are of high relevance. Attempts to improve antidepressants have been made into monoamine-related strategies, but also more recently in non-monoamine strategies. The effectiveness of monoamine-targeted selective, dual- and triple-uptake inhibitors and augmented uptake inhibitors is discussed. In addition, new strategies such as monoamine non-uptake inhibitor drugs or non-monoamine drugs exerting effects on Glu, gamma-aminobutyric acid (GABA), Substance P, and acetylcholine are discussed, as are more miscellaneous approaches.

Type
Chapter
Information
Next Generation Antidepressants
Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders
 , pp. 12 - 27
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Schildkraut, J. J. Am. J. Psychiatry 1965; 122: 509–21.CrossRefGoogle Scholar
Van Praag, H. M., Korf, J., Puite, J. Nature 1970; 225: 1259–60.CrossRefGoogle Scholar
Van Praag, H. M., Korf, J. Psychopharmacologia 1971; 19: 148–52.Google Scholar
Sjostrom, R. Eur. J. Clin. Pharmacol. 1973; 6: 75–80.Google Scholar
Goodwin, F. K., Rubovits, R., Wehr, T. A. Sci. Proc. Am. Psychiatr. Assoc. 1977; 130: 108.Google Scholar
Bowers, M. B. J .Nerv. Ment. Dis. 1974; 158: 325–30.Google Scholar
Faustman, W. O., King, R. J., Faul, K. F., et al. J. Affect. Disord 1991; 22: 235–39.Google Scholar
Meltzer, H. Y., Lowy, M., Robertson, A., et al. Arch. Gen. Psychiatry 1984; 41: 391–97.Google Scholar
Beskow, J., Gottfries, C. G., Roos, B. E., Winblad, D. B. Acta Psychiatr. Scand. 1976; 53: 7–20.Google Scholar
Cheetham, S. C., Crompton, M. R., Czudek, C., et al. Brain Res. 1989; 502: 332–40.Google Scholar
Woolley, D. W., Shaw, E. Science 1954; 119: 587–88.Google Scholar
Gaddum, J. H. Nature 1963; 197: 741–43.Google Scholar
Carlsson, A, Lindqvist, M, Magnusson, T. Nature 1957; 180: 1200.Google Scholar
Fuller, R. W. Life Sci. 1994; 55: 163–67.CrossRefGoogle Scholar
Bosker, F., Vrinten, D., Klompmakers, A., Westenberg, H. Naunyn Schmiedebergs Arch. Pharmacol. 1997; 355: 347–53.CrossRefGoogle Scholar
Cremers, T. I. F. H., Spoelstra, E. N., de Boer, P., et al. Eur. J. Pharmacol. 2000; 397(2–3): 351–57.Google Scholar
Anderson, I. M. Depress. Anxiety 1998; 7: 11–17.Google Scholar
Anderson, I. M., Tomenson, B. M. Br. Med. J. 1995; 310: 1433–38.Google Scholar
Bech, P., Cialdella, P. Int. Clin. Psychopharmacol. 1992; 6(Suppl. 5): 45–54.Google Scholar
Bech, P. In: Dahl, S. G., Gram, L. F., eds. Clinical Pharmacology in Psychiatry. Berlin: Springer, 1989; 81–93.CrossRefGoogle Scholar
Mendlewicz, J. Drugs 1992; 43(Suppl. 2): 32–37.Google Scholar
Montgomery, S. A., Henry, J., McDonald, G., et al. Int. Clin. Psychopharmacol. 1994; 9: 47–53.Google Scholar
Song, F., Freemantle, N., Sheldon, T. A., et al. Br. Med. J. 1993; 306: 683–87.Google Scholar
24. Steffens, D. C., Krishnan, K. R., Helms, M. J. Depress. Anxiety 1997; 6: 10–18.Google Scholar
Tignol, J., Stoker, M. J., Dunbar, G. C. Int. Clin. Psychopharmacol. 1992; 7: 91–94.Google Scholar
Aguglia, E., Casacchia, M., Cassano, G. B., et al. Int. Clin. Psychopharmacol. 1993; 8: 197–202.CrossRefGoogle Scholar
Bennie, E. H., Mullin, J. M., Martindale, J. J. J. Clin. Psychiatry 1995; 56: 229–37.Google Scholar
De Wilde, J., Spiers, R., Mertens, C., et al. Acta Psychiatr. Scand. 1993; 87: 141–45.Google Scholar
Eskelius, L., Von Knorring, L., Eberhard, G. Int. Clin. Psychopharmacol. 1997; 12: 323–31.Google Scholar
Franchini, L., Gasperinin, M., Perez, J., et al. J. Clin. Psychiatry 1997; 58: 104–07.Google Scholar
Geretsegger, C., Bohmer, F., Ludwig, M. Int. Clin. Psychopharmacol. 1994; 9: 25–29.Google Scholar
Haffmans, P. M., Timmerman, L., Hoogduin, C. A. Int. Clin. Psychopharmacol. 1996; 11: 157–64.Google Scholar
Kiev, A., Feiger, A. J., Clin. Psychiatry 1997; 58: 146–52.Google Scholar
Patris, M., Bougerol, T., Charbonnier, J. F., et al. Int. Clin. Psychopharmacol. 1996; 11: 129–36.Google Scholar
Rapaport, M., Coccaro, E., Sheline, Y., et al. J. Clin. Psychopharmacol. 1996; 16: 373–78.Google Scholar
Tignol, J. J. Clin. Psychopharmacol. 1993; 13(Suppl. 2): 18–22.Google Scholar
Baldwin, D. S., Johnson, R. N. Rev. Contemp. Pharmacother. 1995; 6: 315–25.Google Scholar
Cooper, G. L. Br. J. Psychiatry 1988; 15(Suppl. 3): 77–86.Google Scholar
Wagner, W., Zaborny, B. A., Gray, T. E. Int. Clin. Psychopharmacol. 1994; 9: 223–27.CrossRefGoogle Scholar
Boyer, W. F., Blumhardt, C. L. J. Clin. Psychiatry 1992; 53(Suppl.): 61–66.Google Scholar
Doogan, D. P., Caillard, V. Br. J. Psychiatry 1992; 160: 217–22.Google Scholar
Doogan, D. P. Int. Clin. Psychopharmacol. 1991; 6(Suppl. 2): 47–56.CrossRefGoogle Scholar
Keller, M. B., Gelenberg, A. J., Hirschfeld, R. M., et al. J. Clin. Psychiatry 1998; 59: 598–607.Google Scholar
Keller, M. B., Kocsis, J. H., Thase, M. E., et al. JAMA 1998; 280: 1665–72.Google Scholar
Montgomery, S. A., Dunbar, G. C. Int. Clin. Psychopharmacol. 1993; 8: 189–95.Google Scholar
Montgomery, S. A., Henry, J., McDonald, G., et al. Int. Clin. Psychopharmacol. 1994; 9: 47–53.CrossRefGoogle Scholar
Montgomery, S. A., Kasper, S. Int. Clin. Psychopharmacol. 1995; 9(Suppl. 4): 33–40.Google Scholar
Robert, P., Montgomery, S. A. Int. Clin. Psychopharmacol. 1995; 10(Suppl. 1): 29–35.Google Scholar
Rush, A. J., Koran, L. M., Keller, M. B., et al. J. Clin. Psychiatry 1998; 59: 589–97.Google Scholar
Meana, J. J., Barturen, F., Garcia-Sevilla, J. A. Biol. Psychiatry 1992; 1: 471–90.Google Scholar
El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., Haddjeri, N. Neuropsychopharmacology 2005; 30(7): 1269–77.Google Scholar
Dremencov, E., El Mansari, M., Blier, P. J. Psychiatry Neurosci. 2009; 34(3): 223–29.Google Scholar
Dremencov, E., El Mansari, M., Blier, P. Psychopharmacology (Berl). 2007; 194(1) :63–72. Epub 2007 May 27.Google Scholar
Dremencov, E., El Mansari, M., Blier, P. Biol. Psychiatry 2007; 61(5): 671–78. Epub 2006 Aug 24.Google Scholar
Mork, A., Kreilgaard, M., Sanchez, C., Brennum, L. T., Wiborg, O. CINP 2002. P.1.E.054. Montreal.Google Scholar
Wade, A., Lemming, O., Hedegaard, K. B., Poster presented at Scandinavian College of Neuropsychopharmacology (SCNP) 1st Annual Meeting April 18–21, 2001, Juan les Pins, France.Google Scholar
Lepola, U., Loft, H., Reines, E. H. Poster presented at Scandinavian College of Neuropsychopharmacology (SCNP) 1st Annual Meeting, April 18–21, 2001, Juan les Pins, France.Google Scholar
Montgomery, S. A. 2002 Press release (7–10–2002, no. 81).Google Scholar
Burke, W. J. Poster presented at Scandinavian College of Neuropsychopharmacology (SCNP) 1st Annual Meeting, April 18–21, 2001, Juan les Pins, France.Google Scholar
Gorman, J. Poster presented at the 11th Annual Meeting of the Association of European Psychiatrists, May 4–8, 2002, Stockholm.Google Scholar
Rosenthal, M., Zornberg, G., Li, D. CINP 2002. P.3.E.038. Montreal.Google Scholar
Leonard, B. E. J. Psychopharmacology 1997; 11(Suppl. 4): S39–47.Google Scholar
Callado, L. F., Meana, J. J., Grijalba, B., et al. J. Neurochem. 1998; 70: 1114–23.Google Scholar
Charney, D. S., Heninger, G. R., Sternberg, D. E., et al. Arch. Gen. Psychiatry 1981; 38: 1334–40.Google Scholar
Spyraki, C., Fibiger, H. C. Life Sci. 1980; 27: 1863–67.Google Scholar
Sacchetti, G., Bernini, M., Bianchetti, A., et al. Br. J. Pharmacol. 1999; 128(6): 1332–38.Google Scholar
Szabo, S. T., Blier, P. Neuropsychopharmacology 2001; 25(6): 845–57.Google Scholar
Szabo, S. T., Blier, P. Eur. J. Neurosci. 2001; 13(11): 2077–87.Google Scholar
Montgomery, S. A. J. Psychopharmacol. 1997; 11(Suppl. 4): S9–15.Google Scholar
Massana, J., Moller, H. Proc. Ann. Meeting. Am. Psychiatr Assoc., Toronto, Canada 1998.Google Scholar
Dubini, A., Bosc, M., Polin, V. J. Psychopharmacology 1997; 11(Suppl. 4): S17–23.Google Scholar
Katona, C., Bercoff, E., Chiu, E., et al. J. Affect. Disord. 1999; 55: 203–13.Google Scholar
Massana, J. J. Clin. Psychiatry 1998; 59(Suppl. 14): 8–10.Google Scholar
Montgomery, S. A. Int. J. Psychiatry Clin. Pract. 1999; 3(Suppl. 1): S13–17.Google Scholar
Mucci, M. J. Psychopharmacol. 1997; 11: S33–37.Google Scholar
Ban, T. A., Gaszner, P., Aguglia, E., et al. Hum. Psychopharmacol. 1998; 13: 529–39.Google Scholar
Berzewski, H., van Moffaert, M., Gagiano, C. A. Eur. Neuropsychopharmacol. 1997; 7(Suppl. 1): S37–47.Google Scholar
López-Muñoz, F., Alamo, C., Rubio, G., García-García, P., Pardo, A. Pharmacopsychiatry 2007; 40(1): 14–19.Google Scholar
Fava, M. J. Clin. Psychiatry 2000; 61(Suppl 1): 26–32.Google Scholar
Tremblay, P., Blier, P. Curr. Drug Targets 2006; 7(2): 149–58.Google Scholar
Thase, M. E., Nierenberg, A. A., Keller, M. B., Panagides, J. J. Clin. Psychiatry 2001; 62(10): 782–88.Google Scholar
Nestler, E. J., Carlzon, W. A. Biol. Psychiatry 2006; 59: 1151–59.Google Scholar
Corrigan, M. H., Denahan, A. Q., Wright, C. E., Ragual, R. J., Evans, D. L. Depression Anxiety 2000; 11: 58–65.Google Scholar
Prica, C., Hascoet, M., Bourin, M. Behav Brain Res. 2008; 194: 92–99.Google Scholar
Axford, L., Booth, J. R., Hotten, T. M., et al. Bioorg. Med. Chem. Lett. 2003; 13: 3277–80.CrossRefGoogle Scholar
Samaha, A. N., Robinson, T. E. Trends Pharmacol. Sci. 2005; 26: 82–87.Google Scholar
Volkow, N. D., Wang, G. J., Fowler, J. S., et al. Biol. Psychiatry 2005; 57: 640–46.Google Scholar
Millan, M. J. J. Pharmacol. Exp. Ther. 2006: 110: 135–370.Google Scholar
El-Ghundi, M., O’Dowd, B. F., George, S. R. Rev. Neurosci. 2007; 18: 37–66.Google Scholar
Dong, J., Blier, P. Psychopharmacology (Berl.) 2001; 155: 52–57.Google Scholar
Mongeau, R., Blier, P., de Montigny, C. Brain Res. Brain Res. Rev. 1997; 23: 145–95.Google Scholar
Blier, P., Piñeyro, G., el Mansari, M., Bergeron, R., de Montigny, C. Ann. NY Acad. Sci. 1998; 861: 204–16.Google Scholar
Portella, M. J., de Diego-Adeliño, J., Puigdemont, D., et al. Eur. Neuropsychopharmacol. 2009; 19: 516–19.Google Scholar
Lifschytz, T., Segman, R., Shalom, G., et al. Curr. Drug Targets 2006; 7(2): 203–10.Google Scholar
De Paulis, T. IDrugs 2007; 10: 193–201.Google Scholar
Cremers, T. I., Giorgetti, M., Bosker, F. J., et al. Neuropsychopharmacology 2004: 29(10): 1782–89.Google Scholar
Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., for the Agomelatine Study Group. J. Clin. Psychiatry. Epub 2009 Aug 11.Google Scholar
Coupland, N. J., Bailey, J. E., Wilson, S. J., Potter, W. Z., Nutt, D. J. Clin. Pharmacol. Ther. 1994; 56: 420–29.Google Scholar
Thomas, D. R., Soffin, E. M., Roberts, C., et al. Neuropharmacology 2006; 51: 566–77.Google Scholar
Arborelius, L., Owens, M. J., Plotsky, P. M., Nemeroff, C. B. J. Endocrinol. 1999; 160: 1–12.Google Scholar
Lovenberg, T. W., Liaw, C. W., Grigoriadis, D. E., et al. PNAS 1995; 92: 836–40.Google Scholar
Chalmers, D. T., Lovenberg, T. W., De Souza, E. B. J. Neurosci. 1995; 15: 6340–50.Google Scholar
Gold, P. W., Chrousos, G. P. Mol. Psychiatry 2002; 7: 254–75.Google Scholar
Van der Hart, M. Substance P and the Neurokenin 1 Receptor. Groningen, Netherlands, Ipskamo Drukkers BV, 2009.Google Scholar
Guiard, B. P., Lanfumey, L., Gardier, A. M. Curr. Drug Targets 2006; 7: 187–201.Google Scholar
Gobbi, G., Blier, P. Peptides 2005; 26: 1383–93.Google Scholar
Blier, P., Gobbi, G., Haddjeri, N., et al. Psychiatry Neurosci. 2004; 29: 208–18.Google Scholar
Haddjeri, N., Blier, P. Eur. J. Pharmacol. 2008; 600(1–3): 64–70.CrossRefGoogle Scholar
Kramer, M. S., Cutler, N., Feighner, J., et al. Science 1998; 281: 1640–45.Google Scholar
Ranga, K., Krishnan, R. J. Clin. Psychiatry 2002; 63(Suppl. 11): 25–29.Google Scholar
McKay, B. E., Placzek, A. N., Dani, J. A. Biochem. Pharmacol. 2007; 74: 1120–33.Google Scholar
Mansvelder, H. D., Mertz, M., Role, L. W. Semin. Cell Dev. Biol. 2009; 20: 432–40.Google Scholar
Dremencov, E., Gur, E., Lerer, B., Newman, M. E. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003; 27(5): 729–39.Google Scholar
Ischaki, E., Gratziou, C. Ther. Adv. Respir. Dis. 2009; 3: 31–38.Google Scholar
Lising-Enriquez, K., George, T. P. J. Psychiatry Neurosci. 2009; 34: E1–2.Google Scholar
Elgamal, S., MacQueen, G. J. Clin. Psychopharmacol. 2008; 28: 357–59.Google Scholar
Elgamal, S. A., Marriott, M., Macqueen, G. M. J. Clin. Neurophysiol. 2009; 26: 192–97.Google Scholar
Abe, Y., Aoyagi, A., Hara, T., et al. J. Pharmacol. Sci. 2003; 93: 95–105.Google Scholar
Zarate, C. A., Singh, J. B., Quiroz, J. A., et al. Am. J. Psychiatry 2006; 163: 153–55.Google Scholar
Zarate, C. A., Zing, J. B., Carlson, P. J., et al. Arch. Gen. Psychiatry 2006; 63: 856–64.Google Scholar
Maeng, S., Zarate, C. A., Du, J., et al. Biol. Psychiatry 2008; 63: 349–52.Google Scholar
Black, M. D. Psychopharmacology 2005; 179: 154–63.Google Scholar
Rea, K., Dremencov, E., Cremers, T.I.F.M., et al. Augmentation of citalopram response by antagonists of γ-amino-butyric type-B (GABA) receptors. Psychopharmacology 2010; forthcoming.Google Scholar
Cremers, T.I.F.M., Dremencov, E., Bosker, F. J., et al. Benzodiazepines diminish paroxetine-induced elevation of serotorin levels in guinea pig hippocampus Int. J. Neuropsychopharmacol 2010; forthcoming.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×